|
KMID : 0620920190510070070
|
|
Experimental & Molecular Medicine
2019 Volume.51 No. 7 p.70 ~ p.70
|
|
|
C-type natriuretic peptide attenuates renal osteodystrophy through inhibition of FGF-23/MAPK signaling
|
|
Zhang Dong Dong
Wu Yang Fang
Chen Wei Xia
Xu Yao
Liu Si Yan
Luo Huang Huang
Jiang Guang Mei
Wu Yue
Hu Peng
|
|
|
Abstract
|
|
|
|
Renal osteodystrophy (ROD) occurs as early as chronic kidney disease (CKD) stage 2 and seems ubiquitous in almost all pediatric patients with CKD stage 5. Fibroblast growth factor (FGF)-23, a bone-derived endocrine regulator of phosphate homeostasis, is overexpressed in CKD and disturbs osteoblast differentiation and matrix mineralization. In contrast, C-type natriuretic peptide (CNP) acts as a potent positive regulator of bone growth. In the present study, we infused CNP into uremic rats and observed whether CNP could attenuate ROD through the inhibition of FGF-23 cascades. In uremic rats, CNP administration significantly alleviated renal dysfunction, calcium phosphate metabolic disorders, hypovitaminosis D, secondary hyperparathyroidism, the decrease in bone turnover markers and retarded bone pathological progression. More importantly, within FGF-23/mitogen-activated protein kinase (MAPK) signaling, the fibroblast growth factor receptor-1, Klotho and alternative (STAT-1/phospho-STAT-1) elements were upregulated by CNP, whereas FGF-23, RAF-1/phospho-RAF-1, and downstream (ERK/phospho-ERK and P38/phospho-P38) elements were paradoxically underexpressed in bone tissue. Therefore, CNP exerts a therapeutic effect on ROD through inhibition of FGF-23/MAPK signaling at the RAF-1 level.
|
|
|
KEYWORD
|
|
|
Experimental models of disease, Kidney diseases
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|